Sarah Cannon Research Institute/SCRI — Nashville, Tennessee

Sarah Cannon Research Institute/SCRI is a clinical research site located in Nashville, Tennessee, United States 37203.

Crixeo Health Trust Score: 66/100 (FAIR). This profile has not yet been claimed by the site owner.

Sarah Cannon Research Institute/SCRI has participated in 3 clinical trials with 3 currently active.

Therapeutic areas: Breast Neoplasm, Neoplasm Metastasis, Pancreatic Ductal Adenocarcinoma.

Sponsors: Eli Lilly and Company, MBQ Pharma.

Sponsor Feasibility Report

Trust Score: 66/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Sarah Cannon Research Institute/SCRI?

Sarah Cannon Research Institute/SCRI has a Crixeo Trust Score of 66/100 (FAIR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Sarah Cannon Research Institute/SCRI conducted?

Sarah Cannon Research Institute/SCRI has 3 clinical trials on record, with 3 currently active. Their work covers Breast Neoplasm, Neoplasm Metastasis, Pancreatic Ductal Adenocarcinoma.

Is Sarah Cannon Research Institute/SCRI accredited by Crixeo Health?

Sarah Cannon Research Institute/SCRI has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Sarah Cannon Research Institute/SCRI?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.